Sugi Predict

Sugi Predict / Compounds / SCHEMBL1770905

SCHEMBL1770905

SCHEMBL1770905

COC(=O)c1ccc(C)cc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.50
▸ CYP46A1 Q9Y6A2 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.48
▸ MAPT P10636 4/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA7 P43166 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CA14 Q9ULX7 2/20 0.47
▸ PDK2 Q15119 1/20 0.47
▸ PDK4 Q16654 1/20 0.47
▸ XDH P47989 1/20 0.45
▸ GAA P10253 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31541711 0.87 CA12 (0.43) NR4A2CYP46A1TDP1MAPTSMN1; SMN2
SCHEMBL221754 0.85 CYP46A1 (0.53) NR4A2CYP46A1TDP1MAPTSMN1; SMN2
SCHEMBL3839211 0.82 NR4A2 (0.54) NR4A2MAPTSMN1; SMN2CA12CA1
SCHEMBL1206018 0.82 CYP46A1 (0.57) NR4A2CYP46A1TDP1MAPTSMN1; SMN2
SCHEMBL30294421 0.81 TSHR (0.53) TDP1MAPTSMN1; SMN2CA12CA1
SCHEMBL22852761 0.81 TSHR (0.53) TDP1MAPTSMN1; SMN2CA12CA1
SCHEMBL7062473 0.81 CA12 (0.67) NR4A2MAPTSMN1; SMN2CA12CA1
SCHEMBL70233 0.81 KDM4E (0.62) TDP1MAPTSMN1; SMN2CA12CA1
SCHEMBL2305885 0.81 KDM4E (0.57) NR4A2CA12CA1CA2CA7
SCHEMBL7564043 0.80 CISD2 (0.37) TDP1MAPTSMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023086447-A2 A METHOD FOR THE SYNTHESIS OF CANNABINOL PUREFORM GLOBAL, INC. (US) 2023-05-19 — — WO claimed
EP-3692101-B1 BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES ALFA INSTR S R L (IT) 2022-01-12 — — EP claimed
CN-108774206-B Preparation method of compound containing isochroman-1-ketone skeleton 山西大学 2021-11-19 — — CN claimed
EP-3692101-A1 BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES Alfa Instruments S.r.l. (IT) 2020-08-12 — — EP claimed
WO-2019068935-A1 BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES ALFA INSTRUMENTS S.R.L. (IT) 2019-04-11 — — WO claimed
US-12637433-B2 Histone deacetylase inhibitors THE UNIVERSITY OF QUEENSLAND (AU) 2026-05-26 — — US disclosed
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 — — US disclosed
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 — — US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 — — US disclosed
EP-4602028-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2025-08-20 — — EP disclosed
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-06-19 — — US disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 — — US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 — — WO disclosed
EP-0399731-B2 Azaindenes ASTRAZENECA AB (SE) 2001-07-11 — — EP disclosed
US-6150524-A MORPHINAN DERIVATIVES CENES LTD. (GB) 2000-11-21 — — US disclosed
EP-0960111-A1 MORPHINE DERIVATIVES WITH ANALGESIC ACTIVITY NYCOMED IMAGING AS (NO) 1999-12-01 — — EP disclosed
WO-1997022606-A1 MORPHINE DERIVATIVES WITH ANALGESIC ACTIVITY NYCOMED IMAGING AS (NO) 1997-06-26 — — WO disclosed
EP-0399731-B1 Azaindenes ZENECA LTD (GB) 1993-12-08 — — EP disclosed
EP-0399731-A1 Azaindenes ZENECA LIMITED (GB) 1990-11-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP NR4A2 4249/4885CYP46A1 475/4885TDP1 265/4885
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN NR4A2 2276/4885CYP46A1 740/4885TDP1 53/4885
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, SAAL1 NR4A2 1824/4885CYP46A1 2790/4885TDP1 2800/4885
US-12637433-B2 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC3 NR4A2 1579/4885CYP46A1 3969/4885TDP1 162/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 NR4A2 4675/4885CYP46A1 405/4885TDP1 2002/4885
US-12551490-B2 Heterocyclic modulators of lipid synthesis FASN, FADS1, FADS2 NR4A2 1431/4885CYP46A1 68/4885TDP1 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.